Home » Stocks » Prevail Therapeutics

Prevail Therapeutics Inc. (PRVL)

Stock Price: $9.75 USD -0.01 (-0.05%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
After-hours: $9.75 +0.01 (0.05%) Oct 19, 4:42 PM

Stock Price Chart

Key Info

Market Cap 333.42M
Revenue (ttm) n/a
Net Income (ttm) -78.82M
Shares Out 34.21M
EPS (ttm) -2.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $9.75
Previous Close $9.75
Change ($) -0.01
Change (%) -0.05%
Day's Open 10.02
Day's Range 9.69 - 10.21
Day's Volume 186,841
52-Week Range 9.02 - 19.96

More Stats

Market Cap 333.42M
Enterprise Value 226.43M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 34.21M
Float 28.03M
EPS (basic) -2.38
EPS (diluted) -2.65
FCF / Share -2.12
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.93M
Short Ratio 14.32
Short % of Float 6.87%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.48
Revenue n/a
Operating Income -81.06M
Net Income -78.82M
Free Cash Flow -70.86M
Net Cash 106.99M
Net Cash / Share 3.13
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -27.70%
ROE -47.81%
ROIC -330.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 10
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(132.12% upside)
Current: $9.75
Target: 22.62
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-65.80-18.72
Net Income-63.19-19.09
Shares Outstanding28.495.15
Earnings Per Share-2.22-3.71
Operating Cash Flow-55.75-14.01
Capital Expenditures-2.14-0.63
Free Cash Flow-57.89-14.64
Cash & Equivalents16863.11
Total Debt11.278.87
Net Cash / Debt15754.24
Book Value165-18.42
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Prevail Therapeutics Inc.
Country United States
Employees 64
CEO Asa Abeliovich

Stock Information

Ticker Symbol PRVL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PRVL
IPO Date June 20, 2019


Prevail Therapeutics, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.